Loading viewer...
investor_presentation
Format: PDF investor_presentation
Beyond Machines for Antigen Selection: Using ATLAS™ to Enable Novel Cancer Immunotherapies M a r c h 2 0 1 9
Beyond Machines for Antigen Selection:
Using ATLAS™ to Enable Novel Cancer Immunotherapies
M a r c h 2 0 1 92
This presentation contains “forward -looking” statements that are within the meaning of federal securities laws and are based on our management’s
beliefs and assumptions and on information currently available to management. Forward -looking statements include information con cerning our
possible or assumed future results of operations, business strategies, clinical trials and pre -clinical studies, regulatory appr oval of our product
candidates, liquidity position and capital needs, financing plans, industry environment, potential growth opportunities, pote ntial market opportunities
and the effects of competition.
Forward -looking statements include all statements that are not historical facts and can be identified by terms such as “anticipa tes,” “believes,”
“expects,” “could,” “seeks,” “estimates,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “ wou ld” or similar expressions
and the negatives of those terms. Forward -looking statements represent our management’s beliefs and assumptions only as of the d ate of this
presentation. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or combination of which,
could materially affect our results of operations and whether the forward -looking statements ultimately prove to be correct. Fa ctors that may
materially affect our results of operations include, among other things, our ability to progress product candidates in precli nical and clinical trials, the
ability of ATLAS™to identify promising oncology vaccine and immunotherapy product candidates, the scope, rate and progress of our preclinical and
clinical trials and other research and development activities, anticipated timing of new clinical trails, our estimates regar ding the amount of funds we
require to conduct our clinical trials for GEN -009, our plans to commercialize GEN -009, the timing of, and ability to, obtain an d maintain necessary
regulatory approvals for our product candidates, and those listed in our Annual Report on Form 10 -K for the fiscal year ended De cember 31, 2017 and
other filings with the Securities and Exchange Commission (“SEC”). Except as required by law, we assume no obligation to upda te these forward -looking
statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward -looki ng statements, even if
new information becomes available in the future.
You may get copies of our Annual Report on Form 10 -K, Quarterly Report on Form 10 -Q and our other SEC filings for free by visiti ng EDGAR on the SEC
website at http:// www.sec.gov . 3
Selecting the right antigens to enable diverse cancer immunotherapies:
T cell responsesPOWERFUL
cancer subjects•Vaccines & T cell
Compelling investment opportunity
UNIQUE antigen selection platform, ATLAS™
Preview truncated — download the full document for the complete content.
investor_presentation
35 Pages
Suominen Corporation